{"id":"enzalutamide-soft-capsules","safety":{"commonSideEffects":[{"rate":"34","effect":"Fatigue"},{"rate":"21","effect":"Diarrhea"},{"rate":"20","effect":"Hot flashes"},{"rate":"14","effect":"Musculoskeletal pain"},{"rate":"12","effect":"Headache"},{"rate":"8","effect":"Hypertension"},{"rate":"0.5","effect":"Seizures"}]},"_chembl":{"chemblId":"CHEMBL1082407","moleculeType":"Small molecule","molecularWeight":"464.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Enzalutamide competitively inhibits androgen receptor (AR) signaling by blocking ligand binding, preventing AR nuclear localization, and inhibiting AR-mediated transcription. This mechanism suppresses the growth of androgen-dependent prostate cancer cells. The drug is effective in both castration-sensitive and castration-resistant prostate cancer settings.","oneSentence":"Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, preventing androgen-driven gene transcription in prostate cancer cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:46:16.574Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Metastatic castration-resistant prostate cancer (mCRPC)"},{"name":"Non-metastatic castration-resistant prostate cancer (nmCRPC)"},{"name":"Metastatic castration-sensitive prostate cancer (mCSPC)"}]},"trialDetails":[{"nctId":"NCT06894511","phase":"PHASE2","title":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2025-09-11","conditions":"Metastatic Castration Resistant Prostate Cancer (mCRPC)","enrollment":7},{"nctId":"NCT07311694","phase":"PHASE3","title":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2026-02-02","conditions":"PSMA-Positive Progressive Metastatic Castration-Resistant Prostate Cancer","enrollment":370},{"nctId":"NCT07241416","phase":"PHASE3","title":"A Phase III Clinical Study of Rezvilutamide in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-12-05","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC)","enrollment":156},{"nctId":"NCT02007512","phase":"PHASE2","title":"Efficacy and Safety Study of Enzalutamide in Combination With Exemestane in Patients With Advanced Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-12-16","conditions":"Breast Cancer","enrollment":247},{"nctId":"NCT04363164","phase":"PHASE2","title":"Sequential Testosterone and Enzalutamide Prevents Unfavorable Progression","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2020-08-19","conditions":"Castration Resistant Metastatic Prostate Cancer","enrollment":150},{"nctId":"NCT03851640","phase":"PHASE3","title":"A Trial Evaluating the Efficacy and Safety of HC-1119 Soft Capsules in Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC).","status":"RECRUITING","sponsor":"Hinova Pharmaceuticals Inc.","startDate":"2019-04-12","conditions":"MCRPC","enrollment":417},{"nctId":"NCT01889238","phase":"PHASE2","title":"Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Pfizer","startDate":"2013-06-12","conditions":"Advanced, Androgen Receptor Positive Triple Negative Breast Cancer","enrollment":118},{"nctId":"NCT02116582","phase":"PHASE4","title":"A Study to Evaluate Enzalutamide After Abiraterone in Metastatic Castration-Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2014-05-23","conditions":"Metastatic Castration-Resistant Prostate Cancer","enrollment":215},{"nctId":"NCT03177187","phase":"PHASE1, PHASE2","title":"Combination Study of AZD5069 and Enzalutamide.","status":"TERMINATED","sponsor":"Institute of Cancer Research, United Kingdom","startDate":"2017-11-13","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":30},{"nctId":"NCT02453009","phase":"PHASE2","title":"Addition of Enzalutamide to First Line Docetaxel for Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Santa Chiara Hospital","startDate":"2014-10","conditions":"Prostatic Neoplasms","enrollment":246},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT02090114","phase":"PHASE2","title":"RE-sensitizing With Supraphysiologic Testosterone to Overcome REsistance (The RESTORE Study)","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-08-25","conditions":"Prostate Cancer","enrollment":112},{"nctId":"NCT04986176","phase":"PHASE3","title":"HC-1119 Adjuvant Treatment for Hospitalized COVID-19 Patients","status":"UNKNOWN","sponsor":"Applied Biology, Inc.","startDate":"2022-04-15","conditions":"COVID-19 Respiratory Infection","enrollment":602},{"nctId":"NCT02346578","phase":"PHASE2","title":"Comparative Study of Alternative Antiandrogen (AA) Therapy and Early Initiating of Enzalutamide for Castration-resistant Prostate Cancer (CRPC) After Combined Androgen Blockade (CAB) Therapy.","status":"COMPLETED","sponsor":"Taro Iguchi, MD, PHD","startDate":"2014-12","conditions":"Castration-resistant Prostate Cancer","enrollment":104},{"nctId":"NCT02286921","phase":"PHASE2","title":"Testosterone Revival Abolishes Negative Symptoms, Fosters Objective Response and Modulates Enzalutamide Resistance","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2015-01","conditions":"Castration Resistant Metastatic Prostate Cancer","enrollment":222},{"nctId":"NCT02471469","phase":"","title":"Personalizing Enzalutamide Therapy by Understanding the Relation Between Tumor mRNAs, miRNAs and Treatment Response","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-10","conditions":"Metastatic Castration Resistant Prostate Cancer","enrollment":40},{"nctId":"NCT01902251","phase":"PHASE1","title":"Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients","status":"COMPLETED","sponsor":"Astellas Pharma Europe B.V.","startDate":"2012-11","conditions":"Prostate Cancer, Pharmacokinetics of Enzalutamide","enrollment":27}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Enzalutamide Soft Capsules","genericName":"Enzalutamide Soft Capsules","companyName":"Jiangsu HengRui Medicine Co., Ltd.","companyId":"jiangsu-hengrui-medicine-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Enzalutamide is an androgen receptor inhibitor that blocks the binding and nuclear translocation of androgens, preventing androgen-driven gene transcription in prostate cancer cells. Used for Metastatic castration-resistant prostate cancer (mCRPC), Non-metastatic castration-resistant prostate cancer (nmCRPC), Metastatic castration-sensitive prostate cancer (mCSPC).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}